News – Oxford Sciences Innovation

Twitter

Oxford Sciences Innovation @OSI_Updates·

Our portfolio company Quantum Motion are in Forbes!

#quantum #oxfordscience #breakthrough

https://www.forbes.com/sites/adrianbridgwater/2021/05/13/uk-firm-proves-quantum-capability-on-commercial-silicon-chips/?sh=44a5eea4d115

Reply on Twitter 1394270419818094593 Retweet on Twitter 13942704198180945932 Like on Twitter 13942704198180945933 Twitter 1394270419818094593

Retweet on Twitter Oxford Sciences Innovation Retweeted

Ivy Farm @ivyfarm_tech·

15h

Engineers, scientists, researchers, technicians. Dog or cat person, we don’t mind. If you’re a meat lover, passionate about biotechnology and compassionate about animals and the planet, see what roles we’re currently hiring for and join the herd.

http://www.ivy.farm/careers

Reply on Twitter 1394186004915965952 Retweet on Twitter 13941860049159659524 Like on Twitter 13941860049159659526 Twitter 1394186004915965952

Retweet on Twitter Oxford Sciences Innovation Retweeted

Dr Russ Tucker @DrRussTucker·

15 May

Thank you to the UK media outlets for sharing our mission today. We’ll let you all know when we’re ready to fire up the BBQ. - Russ (aka The Hog Father)

@thetimes @dailymailuk, @thesun, @dailymirror, @BBC, @BBCRadio4.

#media #biotechnology #culturedmeat

Reply on Twitter 1393592904015360004 Retweet on Twitter 13935929040153600044 Like on Twitter 13935929040153600044 Twitter 1393592904015360004

Stay up to date with news from OSI and our portfolio

Welcome to the portfolio Ivy Farm Technologies! Find out why Ivy Farm is the future for meat lovers, animal lovers and our planet.

First Light Fusion installs UK’s biggest two-stage hyper-velocity gas gun to advance its projectile fusion technology.

Perspectum partners in a new study in singapore for the early detection of liver cancer using precision medicine

Vaccitech announces closing of $110.5 million initial public offering – the 1st IPO for the OSI portfolio!

Vaccitech announces pricing of initial public offering – the 1st IPO for the OSI portfolio!

Perspectum’s new study shows measurable organ impairment in Long COVID patients

Alexis Dormandy has joined the UK government’s new expert council formed to maximise UK investment offer

OSI UPDATES: SPRING 2021 NEWSLETTER

Oxford Endovascular Ltd raises $10m to develop its origami engineered medical device to prevent brain haemorrhage

Quantum Computing Breakthrough Shows Blueprint for Scalable Future

Perspectum research links high liver fat to increased risk of hospitalization in COVID-19 patients with obesity

Meet the Founders: Cheerag Shirodaria, CEO and Charalambos Antoniades, CSO, Caristo Diagnostics

Caristo Diagnostics announces EU approval for AI technology which can predict heart attacks years in advance

Vaccitech appoints Joseph Scheeren, PharmD, to its Board of Directors

Vaccitech Doses First Patient in HPV001, a Phase 1/2 Clinical Trial of VTP-200 Immunotherapeutic for High-risk Persistent HPV Infection

Vaccitech Completes $168 Million Series B Financing to Advance Three Clinical Programs Through Phase 2 Results

Meet Oxford’s Female Founders & CEOs – watch the recorded event!

International Women’s Day: Meet Oxford’s Female Founders

SpyBiotech announces the appointments of Dan Menichella as Non-Executive Director and Dr Norman Begg as Scientific Advisor

MoA Tech appoints Virginia Corless as CEO

Perspectum Lands Top Spot in Alantra Pharma Fast 50 Rankings

Vaccitech appoints two independent board directors

Genomics Plc completes oversubscribed $30m funding round

PepGen Announces Formation of Scientific Advisory Board

Welcome to the portfolio: T-Cypher Bio

EVOX THERAPEUTICS COMPLETES £69.2 MILLION SERIES C FINANCING

£2.5M for intelligent battery technology start up, Brill Power

SpyBiotech raises $32.5M in Series A funding and appoints Lutz B. Giebel as Chairman

OSI UPDATES: WINTER 2021 NEWSLETTER

Professor Jerry Chittenden joins First Light Fusion’s Advisory Board

PepGen appoints James McArthur, Ph.D., as President and Chief Executive Officer

Scenic Biotech Appoints Dr. Philippe Dro as Independent Chairman

First patient receives Vaccitech’s VTP-300 in a Phase 1b/2a clinical trial. An experimental immunotherapy for chronic HBV, a global health problem affecting over 250 million people

Introducing our first Entrepreneur in Residence from Biopharma: Damian Crowther

John McHutchison joins the board of Evox Therapeutics

Perspectum’s CoverScan MD approved by the UK’s MHRA – the world’s first integrated imaging service capable of mapping the impact of COVID-19 on the body

Ex-Centrica and BP boss Iain Conn joins Oxford Flow board

OQC lab takes delivery of first Proteox worldwide – a significant milestone to building a quantum-powered future

OQC state-of-the-art quantum laboratory opens

Theolytics raises $6.8 million Series A round co-led by Epidarex Capital and Taiho Ventures to advance viral cancer therapies

Ultromics’ first-of-a-kind AI solution to help clinicians diagnose coronary artery disease from echiocardiograms in a matter of minutes approved by the FDA

Bodle Technologies Secures Series A Funding Extension

Perspectum issued CPT® Codes for LiverMultiScan® by the American Medical Association to help Drs diagnose and treat liver disease

Clean nuclear: Oxford start-up 10 years ahead of government targets in race to build fusion plant

LifeArc co-leads £6 million funding in DJS Antibodies

MERRY CHRISTMAS FROM ALL THE TEAM AT OSI

Meet the Founder: Sumi Biswas, CEO of SpyBiotech

PepGen raises $45M in Series A funding, led by RA Capital

HEXR launches smartphone fitting app: Bespoke, 3D printed helmets now accessible to millions

Software Ate the World, and Soon It Will Write Itself – Wall Street Journal article by Diffblue

Counterfeit drugs and illegitimate vaccines, both costly and deadly, could be a thing of the past with new breakthrough testing technology from Proxisense and Oxford University

Refeyn Closes Series A Funding Round, led by Northpond Ventures

The Backstory: Vaccitech and its role in co-inventing the Oxford COVID-19 vaccine

BREAKTHROUGH FOR OXFORD’S COVID VACCINE, CO-INVENTED BY OSI PORTFOLIO COMPANY VACCITECH

Evox Therapeutics launch strategic collaboration with Oxford University to accelerate development of exosome therapies for rare diseases

Mind Foundry raises an additional $13.6 million in Series A funding led by Aioi Nissay Dowa Insurance

OSI UPDATES: AUTUMN 2020 NEWSLETTER

The Backstory: Base Genomics and their mission to defeat cancer through early diagnosis

Oxford Sciences Innovation announces the sale of Base Genomics to Exact Sciences

Vaccitech expands management team with hires including CMO and CFO

Notice of Annual General Meeting

Fusion energy can be the most cost competitive source of baseload power, at the same level as renewables

Oxford Sciences Innovation appoints Alexis Dormandy as CEO

Scenic Biotech Enters into Genetic Modifier Collaboration with Genentech

3 portfolio companies win the NHSX AI in Healthcare Award

SpyBiotech and Serum Institute of India announce that the first subjects have been dosed in a Phase I/II trial of a novel virus-like particle vaccine targeting COVID-19

Biocentury feature: OSI leverages foundational deal with Oxford to build its life sciences portfolio

Celebrating five years of OSI and Oxford’s history of innovation

Meet the Founder: Ilana Wisby, CEO of Oxford Quantum Circuits

The genome only makes sense in 3D, by Lachlan Mackinnon

Orca Computing raises £2.9m in pre-seed funding for photonics quantum computer

Positive Phase 1 readout of Dr Sarah Gilbert covid vaccine

Cybersecurity in the age of quantum: Our investment in PQShield

Evox announces landmark partnerships with pharma giants Takeda and Eli Lilly

Welcome to the portfolio, Base Genomics!

A royal launch of our Grassroots incubator space!

Uciane Scarlett, our Life Sciences principal, on an inclusive biotech sector

Vaccitech CEO Bill Enright on the Oxford Covid-19 vaccine

Ultromics featured in the Wall Street Journal